Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

FIBROSIS

A single-cell atlas of fibroblasts: one size does not fit all

Nature Reviews Gastroenterology & Hepatology volume 18, pages 595–596 (2021)Cite this article

Subjects

Delineation of fibroblast heterogeneity has the potential to identify select mesenchymal populations involved in health and disease. A recent study integrated single-cell transcriptomic data to generate a fibroblast atlas of steady-state and perturbed tissues in mice and humans, showing baseline and context-specific fibroblast phenotypes between species and pathologies, including IBD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Key organizing principles of fibroblast lineages across species in healthy and perturbed tissues.

References

  1. Kulkarni, A., Anderson, A. G., Merullo, D. P. & Konopka, G. Beyond bulk: a review of single cell transcriptomics methodologies and applications. Curr. Opin. Biotechnol. 58, 129–136 (2019).

    Article  CAS  Google Scholar 

  2. Wang, J. et al. Novel mechanisms and clinical trial endpoints in intestinal fibrosis. Immunol. Rev. https://doi.org/10.1111/imr.12974 (2021).

    Article  PubMed  Google Scholar 

  3. Lynch, M. D. & Watt, F. M. Fibroblast heterogeneity: implications for human disease. J. Clin. Invest. 128, 26–35 (2018).

    Article  Google Scholar 

  4. Guerrero-Juarez, C. F. et al. Single-cell analysis reveals fibroblast heterogeneity and myeloid-derived adipocyte progenitors in murine skin wounds. Nat. Commun. 10, 650 (2019).

    Article  CAS  Google Scholar 

  5. Buechler, M. B. et al. Cross-tissue organization of the fibroblast lineage. Nature 593, 575–579 (2021).

    Article  CAS  Google Scholar 

  6. Lu, C. et al. Systematic review: medical therapy for fibrostenosing Crohn’s disease. Aliment. Pharmacol. Ther. 51, 1233–1246 (2020).

    Article  CAS  Google Scholar 

  7. Bettenworth, D. & Rieder, F. Medical therapy of stricturing Crohn’s disease: what the gut can learn from other organs - a systematic review. Fibrogenesis Tissue Repair 7, 5 (2014).

    Article  Google Scholar 

  8. Rieder, F. et al. An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn’s disease. Aliment. Pharmacol. Ther. 48, 347–357 (2018).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge the helpful comments by C. Fiocchi.

Author information

Authors and Affiliations

  1. Henan Key Laboratory of Immunology and Targeted Drug, Xinxiang Medical University, Xinxiang, Henan Province, China

    Jie Wang

  2. Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA

    Jie Wang & Florian Rieder

  3. Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH, USA

    Florian Rieder

Authors
  1. Jie Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Florian Rieder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Florian Rieder.

Ethics declarations

Competing interests

F.R. is Consulting or Advisory Board member for Adnovate, Agomab, Allergan, AbbVie, Arena, Boehringer-Ingelheim, Celgene/BMS, CDISC, Cowen, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Index Pharma, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios and 89Bio. J.W. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, J., Rieder, F. A single-cell atlas of fibroblasts: one size does not fit all. Nat Rev Gastroenterol Hepatol 18, 595–596 (2021). https://doi.org/10.1038/s41575-021-00482-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-021-00482-w

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing